Syndax Pharmaceuticals, Inc.

Exelixis, Inc.

Peter Ordentlich

Robert Goodenow

Lei Wang

Raju Mohan

Richard Martin

Bolin Liu

Serap Sankoh

Michael Meyers

Bob Goodenow

Xiaoping Huang

The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.

Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.

Selection of patients for combination therapy

Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.

Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.

Methods for the treatment of breast cancer

Novel compositions and methods of using substituted pyrimidines which have the general formula: (I). 

Growing community of inventors

Lexington, MA, United States of America

Peter Ordentlich